

H1N1 TESTING REPORT

FabriSafeTM



WHERE MICROBES DIE BY THE SWORD.



Proven efficacy against the Influenza A virus H1N1 Swine

Ref: Against EN14476:2007-02 and reported January 2010 by MikroLab GmbH

Trials on Germ Free 24 recently undertaken and completed in Germany against the Influenza A virus H1N1 Swine for virus inactivation have proven successful.

Successful screen tests completed in December have been followed by a comprehensive quantitative suspension assay using an H1N1 Swine strain obtained in Germany (as surrogate of the pandemic strain influenza), prepared by MikroLab. This was tested following the EN 14476:2007-02 standard test protocol for chemical disinfectants and antiseptics – virucidal quantitative suspension methodology.

These trials undertaken by Dr Jochen Steinmann MD of MikroLab GmbH, a world recognized ZLG accredited German laboratory in applied microbiology, have demonstrated this revolutionary anti-microbial's ability to reduce populations of the Influenza A virus H1N1 Swine by a log reduction factor of >4.63 when exposed for 60 seconds at the commercially supplied concentration. This corresponds to an inactivation of 99.99% and was achieved by engaging refined technique allowing all criteria for verification of the methodology to be fulfilled.

This serves to strongly strengthen and support Germ Free's growing reputation as an innovative antimicrobial approach, key in the protection of primary infection and prevention of cross contamination in the world's food & medical arenas. Unlike other antimicrobials Germ free 24 can remain active on hands for up to 24hrs providing long term protection against a wide range of bacteria, viruses & fungi for world travellers and domestic populations alike, whatever the situation.